Harnessing the power of the human microbiome to treat debilitating diseases is a dynamic and growing field. While early focus has been on reducing episodes of recurrent C. difficile infection, the potential of microbiota-based live biotherapeutics extends beyond infectious diseases.
Rebiotix and other researchers continue to evaluate the boundaries of the microbiome’s potential to address disease, in therapeutic areas including but not limited to:
- Inflammatory Bowel Disease
- Hepatic Encephalopathy
- Multi-drug Resistant Organisms (MDROs)
- Recurrent Urinary Tract Infections
- Immunocompromised status/Oncology
- Neurological disorders
- Metabolic diseases
- Reproductive Medicine/Maternal Health
Careful clinical study, strong scientific research, and direct connections to medical professionals and regulatory agencies will drive the future of microbiome-based therapeutics. As the field expands, we will continue to leverage our expertise to bring novel therapeutic options to physicians and patients world-wide.